Browse All

Current Filters

CLEAR FILTER x

TITLE

Correlations Between Early MRI Parameters and Long-term Clinical Outcomes in Phase 3 and Open-label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis

Author:Arnold, Douglas L.   Freeman, Leorah   Hartung, Hans-Peter   Montalbán, Xavier   Cohen, Jeffrey A.   Bar-Or, Amit   Steinman, Lawrence   DeLuca, John   Cheng, Chun-Yen   Riolo, Jon V.   Silva, Diego   Pachai, Chahin   Cree, Bruce A. C.   

Session Name:P5: MS Prognosis/Epidemiology  

Topic:MS and Inflammatory Disease  

Program Number:P5.010  

Author Institution:NeuroRx Research and Montréal Neurological Institute, McGill University, Montréal, Quebec, Canada, Montréal, QC, Canada  Dell Medical School, The University of Texas at Austin, Austin, Texas, Austin, TX  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany  Brain and Mind Centre, University of Sydney, Australia  Department of Neurology, Medical University of Vienna, Austria  and Palacký University Olomouc, Olomouc, Czech Republic, Olomouc, Czech Republic  Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, Cleveland, OH  Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA  Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University Medical Center, Stanford, California, Stanford, CA  Kessler Foundation, West Orange, New Jersey, and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers - New Jersey Medical School, Newark, New Jersey, Newark, NJ  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, San Francisco, CA  

Safety of the Concurrent Administration of Serotonergic Antidepressants and Ozanimod in Patients With Relapsing Multiple Sclerosis

Author:Naismith, Robert T.   Cohen, Jeffrey A.   Bar-Or, Amit   Comi, Giancarlo   Selmaj, Krzysztof W.   Hartung, Hans-Peter   Sheffield, James K.   Krakovich, Anthony   Cheng, Chun-Yen   Reardon, Jennifer   Riolo, Jon V.   Silva, Diego   Cree, Bruce A. C.   

Session Name:P7: MS Therapeutics 1  

Topic:MS and Inflammatory Disease  

Program Number:P7.013  

Author Institution:Washington University School of MedicineWashington University School of Medicine, St Louis, Missouri, St Louis, MO  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, Cleveland, OH  Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of PennsylvaniaCenter for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelph  Vita-Salute San Raffaele University and Casa di Cura del Policlinico, Milan, Italy, Milan, Italy  Center for Neurology, Lódz, Poland and Collegium Medicum, Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland, Olsztyn, Poland  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf Germany  Brain and Mind Centre, University of Sydney, Australia  Department of Neurology, Medical University of Vienna, Austria  and Palacký University Olomouc, Olomouc, Czech Republic, Olomouc, Germany  Bristol Myers Squibb, Princeton, New Jersey, Princeton, PA  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Weill Institute for Neurosciences, Department of Neurology, University of California San FranciscoWeill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, San Francisco, CA